Navigation Links
15-Minute Data From Phase 3 Study of Avanafil Featured as a Late Breaking Abstract at SMSNA Annual Meeting
Date:11/14/2011

MOUNTAIN VIEW, Calif., Nov. 14, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that new analyses from TA-314, a phase 3 long-term safety and efficacy study of the investigational drug avanafil for the treatment of erectile dysfunction (ED), was presented over the weekend at the 2011 Sexual Medicine Society of North America (SMSNA) Meeting in Las Vegas, NV.  Andrew R. McCullough, MD, Professor of Surgery/Urology at Albany Medical College, presented the analysis of results from the study that showed that avanafil was effective in as early as 15 minutes after dosing when analyzed both by subject and attempt.  Of the subjects attempting intercourse </=15 minutes of dosing, 83% had successful intercourse.  Additionally, eighty percent (80%) of all study-wide sexual attempts made within 15 minutes of dosing were successful.

The study entitled, "An Open-label, Long-term Evaluation of the Safety and Efficacy of Avanafil in Men with Erectile Dysfunction" was presented during the Late Breaking Trials Session on November 12, 2011.  Dr. McCullough concluded that based on the results of the study, this onset of action suggests that avanafil, if approved, is potentially well-suited for on-demand treatment in men with mild to severe ED.

About AvanafilAvanafil is an investigational oral drug being developed for the treatment of erectile dysfunction.  Avanafil is a highly selective phosphodiesterase type 5 (PDE5) inhibitor licensed from Mitsubishi Tanabe Pharma Corporation.  VIVUS owns worldwide development and commercial rights to avanafil for the treatment of sexual dysfunction, with the exception of certain Asian Pacific Rim countries.

About VIVUSVIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health.  The company's lead investigational product in c
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
2. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
3. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
4. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
5. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
6. PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet
7. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
8. Michigan Innovation Equipment Depot Launches Next Phase of Distribution
9. Phase 1b/2a Program Commences for RVX-208
10. Chiltern Early Phase: Fully Integrated and Business Ready
11. Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... Ryan Carfley , Managing Partner at Personify ... Bryan Hamilton, the publisher of the Triangle Business Journal, and ... Research Triangle region of North Carolina. , Just a few ... include the role of social media in recruitment, recruiting ... the unique role that Millennials play in the workplace today. ...
(Date:10/27/2014)... 27, 2014 The “Molecular Diagnostic ... Microbiology), Technology (PCR, INAAT, DNA Sequencing), End User ... Software) - Global Forecast to 2018” provides a ... opportunities, current market trends, and strategies impacting the ... and forecasts of the revenue and share analysis. ...
(Date:10/27/2014)... Janssen Biotech, Inc. and the Crohn,s ... the launch of Get Your Full ... designed to provide resources for people living with ... of nutrition and appropriate therapy in managing IBD. ... with this release, please click: http://www.multivu.com/players/English/7261131-janssen-ccfa-get-your-full-course-for-ibd-wellness-with-sunny-anderson/ ...
(Date:10/25/2014)... Angeles, California (PRWEB) October 23, 2014 ... ), a specialty pharmaceutical company devoted to bringing ... out-licensing partnerships in 2015. , ViaDerma has developed ... which allows for rapid mass transfer of pharmaceutical ... the body to provide immediate localized therapy. The ...
Breaking Biology Technology:Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 2Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 3Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 2Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 3Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 4Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 5Celebrity Cook Sunny Anderson Teams Up With Janssen And Crohn's & Colitis Foundation Of America To Launch Educational Campaign 2Celebrity Cook Sunny Anderson Teams Up With Janssen And Crohn's & Colitis Foundation Of America To Launch Educational Campaign 3Celebrity Cook Sunny Anderson Teams Up With Janssen And Crohn's & Colitis Foundation Of America To Launch Educational Campaign 4ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 2ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 3
... , ... transfer has traditionally been a fast but inefficient method , ... buffer system, transfer efficiency can be greatly increased. In protein , ... elution of the proteins , from a gel and ...
... Introduction , Amplification of ... highly sensitive method capable of copying millions of DNA molecules from , ... extreme sensitivity of this method, , any carry-over ... or extra bands. Carry-over contamination can be avoided by using positive , ...
... Luis A Ugozzoli, Bio-Rad Laboratories, Inc., 2000 Alfred Nobel Drive,Hercules, ... Introduction , ... greatly refined since its advent 16 years ago. Several improvements , ... the way PCR is performed today relative to earlier protocols. ...
Cached Biology Technology:Increased Transfer Efficiency Using a Discontinuous Buffer System With the Trans-Blot SD Cell 2Increased Transfer Efficiency Using a Discontinuous Buffer System With the Trans-Blot SD Cell 3Increased Transfer Efficiency Using a Discontinuous Buffer System With the Trans-Blot SD Cell 4Inactivation of Contaminating Templates in PCR Using High Intensity Ultraviolet Light 2Inactivation of Contaminating Templates in PCR Using High Intensity Ultraviolet Light 3The Gradient Feature: Use in Optimization of Allelic Discrimination Assays, Rev B 2The Gradient Feature: Use in Optimization of Allelic Discrimination Assays, Rev B 3The Gradient Feature: Use in Optimization of Allelic Discrimination Assays, Rev B 4The Gradient Feature: Use in Optimization of Allelic Discrimination Assays, Rev B 5The Gradient Feature: Use in Optimization of Allelic Discrimination Assays, Rev B 6The Gradient Feature: Use in Optimization of Allelic Discrimination Assays, Rev B 7The Gradient Feature: Use in Optimization of Allelic Discrimination Assays, Rev B 8
(Date:10/30/2014)... When most animals begin life, cells immediately begin accepting ... organ. However, mammals, including humans, are special. The cells ... choice – to become the protective placenta or to ... critical first step that research from Michigan State University ... current issue of PLOS Genetics , ...
(Date:10/30/2014)... 2014 – Bacteria in the gastrointestinal tract fulfill ... Yet, these same bacteria can induce strong inflammatory ... the gut and enter the bloodstream. , Although ... the body, chronic or systemic inflammation is linked ... established the involvement of inflammatory processes in the ...
(Date:10/30/2014)... , Oct. 29, 2014  Securus Technologies, ... justice technology solutions for public safety, investigation, ... has deployed exciting enhancements to its THREADS™ ... to provide actionable intelligence and focused leads ... to drive technological innovation through identifying and ...
Breaking Biology News(10 mins):Identifying the source of stem cells 2Breakdown in gut barriers to bacteria may promote inflammation and craving in alcoholics 2Securus Technologies Adds Advanced Features to Its Industry-Leading Investigative Analytics Product 2
... at the Texas Biomedical Research Institute in San Antonio ... of "bad" cholesterol. This discovery could lead to the ... heart disease., "Our findings are important because they provide ... reduce heart disease risk in humans," said Laura Cox, ...
... Dr. Philippe Wernet, chemist Prof. Dr. Athina Zouni of Humboldt ... Accelerator Laboratory and Dr. Junko Yano of the Lawrence Berkeley ... In spite of the fact that all aerobic organisms ... Because as part of photosynthesis, green plants, algae, and cyanobacteria ...
... predicts their political opinions on economic redistribution, according ... , a journal of the Association for Psychological ... psychological scientists Michael Bang Petersen of Aarhus ... Santa Barbara believe that the link may ...
Cached Biology News:4 genes indentified that influence levels of 'bad' cholesterol 2Snap shots of 1 of life's central processes 2Political motivations may have evolutionary links to physical strength 2
... [RS17 ] to PRKAR2 cAMP is ... of cellular functions. cAMP exerts its effects ... which transduces the signal through phosphorylation of ... AMPK is a tetramer composed of two ...
... Rocking Shaker provides the exact agitation ... The very slow to fast speed ... provide a gentle wave motion that ... blotted membranes to achieve faster, more ...
...
... Have you bought a Perkin Elmer UltraVIEW ... using the Andor iXon and iQ software? No ... that upgrade. You keep your existing microscope, lasers, ... will customise it to work with our precision ...
Biology Products: